Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P57768

UPID:
SNX16_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P57768; A8K4D8; Q658L0; Q8N4U3

BACKGROUND:
The protein Sorting nexin-16, identified by the accession number P57768, is integral to intracellular trafficking processes. It is involved in the transport and degradation of proteins, such as EGFR following EGF signaling, and plays a role in the movement of vesicular stomatitis virus nucleocapsids. This protein's function is critical from early to late endosomal stages and in lysosomal transport.

THERAPEUTIC SIGNIFICANCE:
The exploration of Sorting nexin-16's functions offers a promising avenue for the development of novel therapeutic approaches. Given its significant role in protein transport and degradation pathways, targeting SNX16 could lead to breakthroughs in the treatment of diseases associated with these cellular processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.